Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach
CNS Drugs · 2025-03 · 39 (3) · 305-320
DOI: 10.1007/s40263-024-01153-5 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift CNS Drugs, online erschienen am 10.01.2025. Verfasst von Vivien Li und 23 weiteren Autor:innen. Beteiligte Einrichtung: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia. Hauptthemen laut MEDLINE: Drug Repositioning, Multiple Sclerosis, Herpesvirus 4, Human, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 112 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia.
- Multiple Sclerosis Australia, Suite 3.01 18 Flour Mill Way, Summer Hill, NSW, 2130, Australia. fiona.mckay@msaustralia.org.au.
- Immunology and Infectious Diseases, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, 2601, Australia.
- Immunology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.
- University of Newcastle, School of Medicine and Public Health, Hunter Medical Research Institute, New Lambton Heights, NSW, 2305, Australia.
- Department of Neurology, John Hunter Hospital, New Lambton Heights, NSW, 2305, Australia.
ORCID-Profile: Vivien Li, Fiona C McKay, David C Tscharke, Corey Smith, Rajiv Khanna, Jeannette Lechner-Scott, William D Rawlinson, Andrew R Lloyd, Bruce V Taylor, Julia M Morahan, Lawrence Steinman, Gavin Giovannoni, Amit Bar-Or, Michael Levy, Erin C Brady, Suzanne Hodgkinson, Todd A Hardy, Simon A Broadley
Zitieren
APA
Li, V., McKay, F. C., Tscharke, D. C., Smith, C., Khanna, R., Lechner-Scott, J., Rawlinson, W. D., Lloyd, A. R., Taylor, B. V., Morahan, J. M., Steinman, L., Giovannoni, G., Bar-Or, A., Levy, M., Drosu, N., Potter, A., Caswell, N., Smith, L., Brady, E. C., …, & Australian Anti-EBV Drugs for MS Working Group (2025). Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach. CNS Drugs, 39(3), 305-320. https://doi.org/10.1007/s40263-024-01153-5
Vancouver
Li V, McKay FC, Tscharke DC, Smith C, Khanna R, Lechner-Scott J, et al. Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach. CNS Drugs. 2025;39(3):305-320. doi:10.1007/s40263-024-01153-5
BibTeX
@article{Li2025,
author = {Li, Vivien and McKay, Fiona C and Tscharke, David C and Smith, Corey and Khanna, Rajiv and Lechner-Scott, Jeannette and Rawlinson, William D and Lloyd, Andrew R and Taylor, Bruce V and Morahan, Julia M and Steinman, Lawrence and Giovannoni, Gavin and Bar-Or, Amit and Levy, Michael and Drosu, Natalia and Potter, Andrew and Caswell, Nigel and Smith, Lynne and Brady, Erin C and Frost, Bruce and Hodgkinson, Suzanne and Hardy, Todd A and Broadley, Simon A and Australian Anti-EBV Drugs for MS Working Group, Australian Anti-EBV Drugs for MS Working Group},
title = {Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach},
journal = {CNS Drugs},
year = {2025},
volume = {39},
number = {3},
pages = {305--320},
doi = {10.1007/s40263-024-01153-5}
}
EUVIMED